{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:15:54Z","timestamp":1791407754644,"version":"4.3.3"},"reference-count":267,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2021-NR060097"],"award-info":[{"award-number":["RS-2021-NR060097"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-00559406"],"award-info":[{"award-number":["RS-2025-00559406"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2026-25476410"],"award-info":[{"award-number":["RS-2026-25476410"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.apsb.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T06:41:31Z","timestamp":1773556891000},"page":"3292-3314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting cytokine\/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Jung Hee","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongbin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Sun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.03.017_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.03.017_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1084887","article-title":"Towards a consensus definition of immune exclusion in cancer","volume":"14","author":"Tiwari","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib4","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2026.03.017_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib7","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.017_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.017_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.03.017_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. a dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.017_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jconrel.2023.03.047","article-title":"Unlocking the promise of systemic STING agonist for cancer immunotherapy","volume":"357","author":"Sun","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.03.017_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.03.017_bib16","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1158\/1078-0432.CCR-06-1372","article-title":"CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas","volume":"12","author":"Redjal","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2326-6066.CIR-24-0324","article-title":"Combination CXCR4 and PD-1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma","volume":"13","author":"Morita","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib18","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.03.017_bib19","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.03.017_bib20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib22","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1038\/s41467-023-39035-x","article-title":"Nanovesicles loaded with a TGF-\u03b2 receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib23","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1554499","article-title":"Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1517147","article-title":"Physical parameters and biological factors affect the abscopal effect of combining radiotherapy with immunotherapy: an update on preclinical works","volume":"12","author":"Ren","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.apsb.2026.03.017_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib28","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2026.03.017_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102345","article-title":"The multifaceted roles of CD4+ T cells and MHC class II in cancer surveillance","volume":"83","author":"Bawden","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3892\/ijo.2022.5374","article-title":"Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment","volume":"61","author":"Zhang","year":"2022","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib31","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.017_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/mt.2011.57","article-title":"Engineering dendritic cells to enhance cancer immunotherapy","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.1901358","article-title":"TNF-\u03b1 regulates human plasmacytoid dendritic cells by suppressing IFN-\u03b1 production and enhancing T cell activation","volume":"206","author":"Psarras","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.scib.2024.01.025","article-title":"Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy","volume":"69","author":"Qian","year":"2024","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.apsb.2026.03.017_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12032-023-02204-5","article-title":"TGF-\u03b2 in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer","volume":"40","author":"Singh","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639636","article-title":"Current advance of immune evasion mechanisms and emerging immunotherapies in renal cell carcinoma","volume":"12","author":"Jian","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib38","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/cancers14133293","article-title":"The desmoplastic stroma of pancreatic cancer: multilayered levels of heterogeneity, clinical significance, and therapeutic opportunities","volume":"14","author":"Masugi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.03.017_bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13058-020-01282-x","article-title":"Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients","volume":"22","author":"Gole","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib41","article-title":"Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds","volume":"7","author":"Wang","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.03.017_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15430\/JCP.2020.25.4.213","article-title":"Recent advances in the development of TGF-\u03b2 signaling inhibitors for anticancer therapy","volume":"25","author":"Lee","year":"2020","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.apsb.2026.03.017_bib44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.017_bib45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib46","article-title":"The chemokines initiating and maintaining immune hot phenotype are prognostic in ICB of HNSCC","volume":"13","author":"Huang","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.apsb.2026.03.017_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601756","article-title":"Chemokines: humble yet mighty players in the tumour microenvironment","volume":"16","author":"Xavier","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib49","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of tumor escape phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib50","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3389\/fimmu.2020.01402","article-title":"Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma","volume":"11","author":"DeCordova","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2026.03.017_bib52","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/bjc.2017.336","article-title":"Interleukin-10-regulated tumour tolerance in non-small cell lung cancer","volume":"117","author":"Vahl","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12307-018-0215-3","article-title":"Ascites IL-10 promotes ovarian cancer cell migration","volume":"11","author":"Lane","year":"2018","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.apsb.2026.03.017_bib54","first-page":"21","article-title":"Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation","volume":"8","author":"Yu","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.apsb.2026.03.017_bib55","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.7150\/thno.113727","article-title":"Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: from mechanism to intervention","volume":"15","author":"Wu","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2026.03.017_bib56","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3892\/ol.2025.15344","article-title":"CCL2\/CCR2 signaling pathway in tumorigenesis and metastasis","volume":"30","author":"Zhang","year":"2025","journal-title":"Oncol Lett"},{"key":"10.1016\/j.apsb.2026.03.017_bib57","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib58","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib59","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022111556","article-title":"The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80","volume":"42","author":"Kennedy","year":"2023","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2026.03.017_bib60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib61","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011944","article-title":"Universal Fab-Fc masked cytokine prodrug platform: \u03b1PD-L1\/IL-15 prodrug activates CD44+ CD8+ T cells in tumor-draining lymph nodes to enhance antitumor immunity","volume":"13","author":"Song","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib64","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2326-6066.CIR-18-0711","article-title":"IRF1 inhibits antitumor immunity through the upregulation of PD-L1 in the tumor cell","volume":"7","author":"Shao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib65","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1452212","article-title":"PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9\/10-CXCR3-IFN\u03b3 positive feedback loop","volume":"15","author":"Abdala-Saleh","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib67","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib68","first-page":"1352","article-title":"IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy","volume":"24","author":"Cui","year":"2025","journal-title":"EXCLI J"},{"key":"10.1016\/j.apsb.2026.03.017_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk7695","article-title":"Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity","volume":"10","author":"Niu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.03.017_bib70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.03.017_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142116","article-title":"Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","article-title":"Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2019.04.057","article-title":"Natural killer cells involved in tumour immune escape of hepatocellular carcinomar","volume":"73","author":"Han","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2026.03.017_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002467","article-title":"Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer","volume":"9","author":"Zeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib75","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MOG.0000000000000613","article-title":"Immune contexture of cholangiocarcinoma","volume":"36","author":"Paillet","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.apsb.2026.03.017_bib76","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.017_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.03.017_bib78","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.017_bib79","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib80","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","article-title":"CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer","volume":"7","author":"Maeda","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib81","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028449","article-title":"The common cytokine receptor \u03b3 chain family of cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib82","article-title":"The application of interleukin-2 family cytokines in tumor immunotherapy research","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib83","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib85","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41587-022-01510-z","article-title":"A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy","volume":"41","author":"Quijano-Rubio","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2026.03.017_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib87","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/fon-2021-1286","article-title":"PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III\/IV melanoma at high risk for recurrence","volume":"18","author":"Eggermont","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2026.03.017_bib89","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib90","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib92","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI44952","article-title":"IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells","volume":"121","author":"Fisher","year":"2011","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib94","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib96","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib97","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-016-0309-7","article-title":"Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report","volume":"9","author":"Uemura","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib98","article-title":"The role of IL-7 and IL-7R in cancer pathophysiology and immunotherapy","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh9879","article-title":"Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity","volume":"9","author":"Kang","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.03.017_bib100","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-21-0947","article-title":"Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models","volume":"28","author":"Campian","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib101","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20071681","article-title":"Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets","volume":"205","author":"Sport\u00e8s","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12488-z","article-title":"Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells","volume":"7","author":"Ding","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.017_bib103","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/bloodadvances.2018021063","article-title":"STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells","volume":"2","author":"Ribeiro","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.apsb.2026.03.017_bib104","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1172\/JCI65459","article-title":"Th9 cells promote antitumor immune responses in vivo","volume":"122","author":"Lu","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12964-020-00538-5","article-title":"IL-9 and IL-9-producing cells in tumor immunity","volume":"18","author":"Wan","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.apsb.2026.03.017_bib106","article-title":"The role of CD4+ T cells in tumor and chronic viral immune responses","volume":"2023","author":"Xie","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.apsb.2026.03.017_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859738","article-title":"IL-9 producing tumor-infiltrating lymphocytes and Treg subsets drive immune escape of tumor cells in non-small cell lung cancer","volume":"13","author":"Heim","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib108","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.3390\/cancers13246301","article-title":"Interleukin (IL)-9 supports the tumor-promoting environment of chronic lymphocytic leukemia","volume":"13","author":"Patrussi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.03.017_bib109","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2021.02.014","article-title":"IL-10 derived from hepatocarcinoma cells improves human induced regulatory T cells function via JAK1\/STAT5 pathway in tumor microenvironment","volume":"133","author":"Zhang","year":"2021","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","article-title":"Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases","volume":"72","author":"Sullivan","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2026.03.017_bib111","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","article-title":"IL-10 directly activates and expands tumor-resident CD8+ T cells without de novo infiltration from secondary lymphoid organs","volume":"72","author":"Emmerich","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947568","article-title":"The multifaceted role of STAT3 in NK-cell tumor surveillance","volume":"13","author":"Witalisz-Siepracka","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib113","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317706209","article-title":"Stimulatory role of interleukin 10 in CD8+ T cells through STATs in gastric cancer","volume":"39","author":"Xi","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib114","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.3390\/cimb46100686","article-title":"Interleukin-12 delivery strategies and advances in tumor immunotherapy","volume":"46","author":"Dong","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009712","article-title":"Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models","volume":"12","author":"Fabian","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib116","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12672-024-01011-2","article-title":"Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity","volume":"15","author":"Xu","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20041057","article-title":"Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function","volume":"201","author":"Zeng","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.017_bib119","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","volume":"43","author":"Ma","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib120","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib121","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.apsb.2026.03.017_bib122","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/UPJ.0000000000000517","article-title":"Quality of life in the phase 2\/3 trial of N-803 plus bacillus calmette-gu\u00e9rin in bacillus calmette-gu\u00e9rin\u2012unresponsive nonmuscle-invasive bladder cancer","volume":"11","author":"Chamie","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.apsb.2026.03.017_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1196829","article-title":"Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models","volume":"14","author":"Papaevangelou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib124","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40364-024-00586-w","article-title":"Lung cancer cell-intrinsic IL-15 promotes cell migration and sensitizes murine lung tumors to anti-PD-L1 therapy","volume":"12","author":"Hu","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib125","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3389\/fimmu.2019.01818","article-title":"The TNF paradox in cancer progression and immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib127","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200434RR","article-title":"TNF-\u03b1-dependent lung inflammation upregulates PD-L1 in monocyte-derived macrophages to contribute to lung tumorigenesis","volume":"36","author":"Wen","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2026.03.017_bib128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/biomedicines11010173","article-title":"The immunosuppressive effect of TNFR2 expression in the colorectal cancer microenvironment","volume":"11","author":"Mohd Salim","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2026.03.017_bib129","first-page":"560","article-title":"Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis","volume":"118","author":"Popivanova","year":"2008","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.725473","article-title":"The TNF-\u03b1\/TNFR2 pathway: targeting a brake to release the anti-tumor immune response","volume":"9","author":"Moatti","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib131","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1172\/JCI64115","article-title":"TNF signaling drives myeloid-derived suppressor cell accumulation","volume":"122","author":"Zhao","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib132","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.celrep.2015.08.033","article-title":"TNF counterbalances the emergence of M2 tumor macrophages","volume":"12","author":"Kratochvill","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.017_bib133","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"Melssen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib136","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1634\/theoncologist.2012-0123","article-title":"U.S. Food and Drug Administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma","volume":"17","author":"Herndon","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.apsb.2026.03.017_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219829","article-title":"Empowering therapeutic antibodies with IFN-\u03b1 for cancer immunotherapy","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.03.017_bib138","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139603","article-title":"Interferon-\u03b2 modulates the innate immune response against glioblastoma initiating cells","volume":"10","author":"Wolpert","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.03.017_bib140","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib141","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib142","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12072-025-10824-4","article-title":"Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial","volume":"19","author":"Qin","year":"2025","journal-title":"Hepatol Int"},{"key":"10.1016\/j.apsb.2026.03.017_bib143","article-title":"A dual role of type I interferons in antitumor immunity","volume":"4","author":"Zhou","year":"2020","journal-title":"Adv Biosyst"},{"key":"10.1016\/j.apsb.2026.03.017_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113683","article-title":"Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1\/2 (IFN\u03b3R1\/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway","volume":"155","author":"Ding","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2026.03.017_bib145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.intimp.2017.04.003","article-title":"IFN\u03b3 enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells","volume":"47","author":"Shao","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2026.03.017_bib146","doi-asserted-by":"crossref","first-page":"89998","DOI":"10.18632\/oncotarget.21286","article-title":"Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer","volume":"8","author":"Kistner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2026.03.017_bib147","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","article-title":"Low-dose IFN\u03b3 induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib148","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-023-40028-z","article-title":"A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors","volume":"14","author":"Zibelman","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib149","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib151","article-title":"CXCL5: a coachman to drive cancer progression","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib152","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1111\/cas.13809","article-title":"Chemokine (C\u2013X\u2013C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid-derived suppressor cells","volume":"109","author":"Shi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib153","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2511","article-title":"Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme","volume":"7","author":"Hu","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.03.017_bib154","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-025-03765-3","article-title":"CXCL2: a key player in the tumor microenvironment and inflammatory diseases","volume":"25","author":"Lv","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.apsb.2026.03.017_bib155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbcan.2019.01.005","article-title":"Potential roles and targeted therapy of the CXCLs\/CXCR2 axis in cancer and inflammatory diseases","volume":"1871","author":"Cheng","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib156","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/cam4.4567","article-title":"Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer","volume":"11","author":"Deng","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib157","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ijc.28673","article-title":"Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression","volume":"135","author":"Kuo","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib158","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-16-2748","article-title":"Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer","volume":"23","author":"Schott","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib159","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.7150\/jca.40517","article-title":"CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration","volume":"11","author":"Zhang","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib160","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1007\/s12094-023-03126-4","article-title":"Targeting CXCL9\/10\/11\u2013CXCR3 axis: an important component of tumor-promoting and antitumor immunity","volume":"25","author":"Pan","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib161","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib162","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-025-02481-w","article-title":"Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy","volume":"24","author":"Coelho","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib163","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.3390\/ijms25126532","article-title":"Chemokines and cytokines in immunotherapy of melanoma and other tumors: from biomarkers to therapeutic targets","volume":"25","author":"Reschke","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1556196","article-title":"CXCR3 inhibitors for therapeutic interventions: current status and perspectives","volume":"16","author":"Huo","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.017_bib165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/cells8060613","article-title":"The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment","volume":"8","author":"Reynders","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.017_bib166","article-title":"The role of CXCR3 and its ligands in cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib167","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1158\/0008-5472.CAN-19-0024","article-title":"CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC","volume":"79","author":"Becker","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib168","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2501791122","article-title":"Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy","volume":"122","author":"Lugassy","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.017_bib169","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13115","article-title":"Role of the CCL2\u2013CCR2 signalling axis in cancer: mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.apsb.2026.03.017_bib170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2\u2013CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib171","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the CCL2\/CCR2 axis in cancer immunotherapy: one stone, three birds?","volume":"12","author":"Fei","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib172","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.imlet.2003.12.009","article-title":"Impact of tumor-derived CCL2 on T cell effector function","volume":"91","author":"Vitiello","year":"2004","journal-title":"Immunol Lett"},{"key":"10.1016\/j.apsb.2026.03.017_bib173","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13046-024-03002-1","article-title":"Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer","volume":"43","author":"Yang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib174","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","article-title":"RANTES: a versatile and controversial chemokine","volume":"22","author":"Appay","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib175","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","article-title":"Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth","volume":"189","author":"Schlecker","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib176","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.03.017_bib177","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/08923973.2017.1417997","article-title":"Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer","volume":"40","author":"Yang","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.apsb.2026.03.017_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008722","article-title":"CCR5 and CCL5 in metastatic colorectal cancer","volume":"12","author":"Schlechter","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib179","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007939","article-title":"CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value","volume":"12","author":"Battaglin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000131","article-title":"CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency","volume":"8","author":"Li","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib181","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41422-021-00528-3","article-title":"Pericytes augment glioblastoma cell resistance to temozolomide through CCL5\u2013CCR5 paracrine signaling","volume":"31","author":"Zhang","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib182","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350847","article-title":"Cenicriviroc, a CCR2\/CCR5 antagonist, promotes the generation of type 1 regulatory T cells","volume":"54","author":"Madan","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib183","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/107999001753289497","article-title":"Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts","volume":"21","author":"Kim","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.10.007","article-title":"PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients","volume":"34","author":"Naing","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib185","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1039\/C9BM00393B","article-title":"Chitosan\/poly(\u03b3-glutamic acid) nanoparticles incorporating IFN-\u03b3 for immune response modulation in the context of colorectal cancer","volume":"7","author":"Castro","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib186","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.apsb.2021.11.004","article-title":"Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment","volume":"12","author":"Shang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.017_bib187","first-page":"2127","article-title":"Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis","volume":"51","author":"Loeffler","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib188","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1081\/DDC-100102262","article-title":"Sustained-release interleukin-12 microspheres in the treatment of cancer","volume":"25","author":"Shah","year":"1999","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2026.03.017_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119417","article-title":"Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines","volume":"220","author":"Da Silva","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.03.017_bib190","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s10495-024-02032-6","article-title":"Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy","volume":"30","author":"Yan","year":"2025","journal-title":"Apoptosis"},{"key":"10.1016\/j.apsb.2026.03.017_bib191","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/acsnano.4c11250","article-title":"Cationic magnetic nanoparticles activate natural killer cells for the treatment of glioblastoma","volume":"19","author":"Rao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.03.017_bib192","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1021\/acs.nanolett.4c01267","article-title":"Sustained secretion of CCL21 via an implantable cell reservoir hydrogel enhances the systemic antitumor effect of radiotherapy","volume":"24","author":"Gao","year":"2024","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2026.03.017_bib193","article-title":"Engineering strategies for immunomodulatory cytokine therapies\u2014challenges and clinical progress","volume":"4","author":"Pires","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib194","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153604","article-title":"Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2026.03.017_bib195","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220745","article-title":"An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery","volume":"219","author":"Shen","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib196","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-21-0058","article-title":"An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity","volume":"9","author":"Xu","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib197","doi-asserted-by":"crossref","first-page":"32431","DOI":"10.1021\/jacs.4c08327","article-title":"Nanoenabled IL-15 superagonist via conditionally stabilized protein\u2013protein interactions eradicates solid tumors by precise immunomodulation","volume":"146","author":"Chen","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.03.017_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123047","article-title":"Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy","volume":"317","author":"Yu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2026.03.017_bib199","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jconrel.2009.10.027","article-title":"Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure","volume":"142","author":"Suzuki","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.03.017_bib200","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","article-title":"PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy","volume":"12","author":"Koerner","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib201","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.actbio.2021.04.034","article-title":"Co-delivery of IL-12 cytokine gene and cisplatin prodrug by a polymetformin-conjugated nanosystem for lung cancer chemo-gene treatment through chemotherapy sensitization and tumor microenvironment modulation","volume":"128","author":"Sun","year":"2021","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2026.03.017_bib202","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbrc.2015.05.065","article-title":"Delivery of human NKG2D\u2013IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity","volume":"463","author":"Yan","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib203","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.03.017_bib204","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1021\/acs.nanolett.2c01994","article-title":"Injectable immunotherapeutic hydrogel containing RNA-loaded lipid nanoparticles reshapes tumor microenvironment for pancreatic cancer therapy","volume":"22","author":"Gao","year":"2022","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2026.03.017_bib205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1039\/D0NH00588F","article-title":"Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Nanoscale Horiz"},{"key":"10.1016\/j.apsb.2026.03.017_bib206","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12645-022-00116-z","article-title":"Delivery of CXCL9\/10\/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer","volume":"13","author":"Ma","year":"2022","journal-title":"Cancer Nano"},{"key":"10.1016\/j.apsb.2026.03.017_bib207","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2026.03.017_bib208","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2358590","article-title":"CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival","volume":"13","author":"Nie","year":"2024","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2026.03.017_bib209","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-015-0063-3","article-title":"NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade","volume":"3","author":"Kohlhapp","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib210","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20130678","article-title":"Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection","volume":"210","author":"Vom Berg","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib211","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12967-024-05620-x","article-title":"Targeting TNFR2 for cancer immunotherapy: recent advances and future directions","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib212","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-21-0496","article-title":"IL15 and anti-PD-1 augment the efficacy of agonistic intratumoral anti-CD40 in a mouse model with multiple TRAMP-C2 tumors","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib213","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib214","article-title":"Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models","volume":"7","author":"Lewis","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2026.03.017_bib215","article-title":"Antitumor activity of pegylated human interferon \u03b2 as monotherapy or in combination with immune checkpoint inhibitors via tumor growth inhibition and dendritic cell activation","volume":"393\u2013394","author":"Wang","year":"2023","journal-title":"Cell Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib216","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-\u03b1 directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib217","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","article-title":"IFN\u03b1 potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment","volume":"12","author":"Hu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.017_bib218","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1047584","article-title":"Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages","volume":"4","author":"Kakizaki","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2026.03.017_bib219","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/brain\/awae347","article-title":"CCL2 blockade combined with PD-1\/P-selectin immunomodulators impedes breast cancer brain metastasis","volume":"148","author":"Israeli Dangoor","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.apsb.2026.03.017_bib220","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib221","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1073\/pnas.1910856117","article-title":"CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas","volume":"117","author":"Flores-Toro","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.017_bib222","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13046-024-03122-8","article-title":"CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN\/AKT signaling phosphorylation and neutrophil chemotaxis","volume":"43","author":"Sun","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib223","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2026.03.017_bib224","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-019-03172-5","article-title":"Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment","volume":"143","author":"Wu","year":"2019","journal-title":"J Neuro Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.06.006","article-title":"A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis","volume":"43","author":"Qian","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib226","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fimmu.2019.00147","article-title":"Support of tumor endothelial cells by chemokine receptors","volume":"10","author":"Salazar","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.017_bib227","first-page":"2322","article-title":"Tumor angiogenesis modulates leukocyte\u2013vessel wall interactions in vivo by reducing endothelial adhesion molecule expression","volume":"63","author":"Dirkx","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib228","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/ijms23042313","article-title":"Perspectives on vascular regulation of mechanisms controlling selective immune cell function in the tumor immune response","volume":"23","author":"Welsh","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.017_bib229","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","article-title":"VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma","volume":"4","author":"Wu","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40364-021-00312-w","article-title":"Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment","volume":"9","author":"Chen","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib231","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1096\/fj.14-250985","article-title":"VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-\u03baB-induced endothelial activation","volume":"29","author":"Huang","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2026.03.017_bib232","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","article-title":"Direct and indirect regulation of the tumor immune microenvironment by VEGF","volume":"111","author":"Zhang","year":"2022","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib233","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib234","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jconrel.2023.11.044","article-title":"CCL2 chemokine inhibition primes the tumor vasculature for improved nanomedicine delivery and efficacy","volume":"365","author":"M\u00f6ckel","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.03.017_bib235","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/s41388-019-1141-7","article-title":"CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments","volume":"39","author":"Brummer","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.03.017_bib236","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216263","article-title":"CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer","volume":"567","author":"Yan","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.03.017_bib237","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/adhm.201500618","article-title":"Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells","volume":"4","author":"Verbeke","year":"2015","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2026.03.017_bib238","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00262-022-03209-1","article-title":"In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy","volume":"71","author":"Tang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2026.03.017_bib239","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1016\/j.vaccine.2022.05.060","article-title":"Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-\u03b2-cyclodextrin: a phase 1 clinical trial","volume":"40","author":"Watanabe","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2026.03.017_bib240","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.3892\/mmr.2015.3950","article-title":"Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine","volume":"12","author":"Gong","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2026.03.017_bib241","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.03.017_bib242","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.017_bib243","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2514040","article-title":"Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models","volume":"14","author":"Pojar","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2026.03.017_bib244","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/annonc\/mdf105","article-title":"A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population","volume":"13","author":"Clark","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12863-023-01139-0","article-title":"The single-cell transcriptome and chromatin accessibility datasets of peripheral blood mononuclear cells in Chinese holstein cattle","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Genom Data"},{"key":"10.1016\/j.apsb.2026.03.017_bib246","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.matbio.2023.07.003","article-title":"The extracellular matrix\u2013immune microenvironment crosstalk in cancer therapy: challenges and opportunities","volume":"121","author":"Closset","year":"2023","journal-title":"Matrix Bio"},{"key":"10.1016\/j.apsb.2026.03.017_bib247","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib248","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1519","article-title":"Strategies to improve tumor penetration of nanomedicines through nanoparticle design","volume":"11","author":"Zhang","year":"2019","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.apsb.2026.03.017_bib249","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nano.2012.07.002","article-title":"Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure","volume":"9","author":"Torosean","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2026.03.017_bib250","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib251","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib252","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.017_bib253","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.017_bib254","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00280-010-1326-9","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjuvant pegylated interferon \u03b1-2b in patients with resected high-risk melanoma","volume":"67","author":"Daud","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.017_bib255","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib256","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.apsb.2026.03.017_bib257","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/cpt.3751","article-title":"Tocilizumab dosing for management of T cell-engaging bispecific antibody-related CRS in patients with R\/R B-Cell NHL","volume":"118","author":"Jamois","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.apsb.2026.03.017_bib258","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine\u2013receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.017_bib259","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41589-025-01986-1","article-title":"Conversion of natural cytokine receptors into orthogonal synthetic biosensors","volume":"21","author":"Edelstein","year":"2025","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.017_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102937","article-title":"Harnessing cytokine immunocomplexes and cytokine fusion proteins for cancer therapy: mechanisms and clinical potential","volume":"136","author":"Kong","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2026.03.017_bib261","article-title":"Cytokine conjugation to enhance T cell therapy","volume":"120","author":"Liu","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.017_bib262","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","article-title":"Spatial profiling technologies illuminate the tumor microenvironment","volume":"41","author":"Elhanani","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.03.017_bib263","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.017_bib264","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2026.03.017_bib265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10020-024-01036-x","article-title":"Multi-omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study","volume":"31","author":"Ye","year":"2025","journal-title":"Mol Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib266","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"npj Digit Med"},{"key":"10.1016\/j.apsb.2026.03.017_bib267","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1076883","article-title":"Advances in artificial intelligence to predict cancer immunotherapy efficacy","volume":"13","author":"Xie","year":"2023","journal-title":"Front Immunol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352600170X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221138352600170X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:23:55Z","timestamp":1783034635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221138352600170X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":267,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S221138352600170X"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.017","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cytokine\/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}